Search - tctmd.com

Displaying 481 - 500 of 681

Sort: Relevancy | Date

News Industry News

Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013

May 17, 2013

News Daily News

Novel Anticoagulants Cost-Effective vs. Warfarin in A-fib Patients

Caitlin E. Cox

May 13, 2013

News Daily News

El Apixaban Superior a la Warfarin con independencia del Tipo y Duración de la FA

May 13, 2013

News Daily News

Apixaban Superior to Warfarin Regardless of A-fib Type, Duration

May 13, 2013

News Industry News

New Four-Year Data From Boston Scientific Demonstrated WATCHMAN® Device Was Superior To Warfarin For Mortality And Primary Efficacy In Patients With Atrial Fibrillation In Long Term Follow-Up Of The P

May 09, 2013

News Industry News

BIOTRONIK continues 50-year legacy of engineering excellence with smaller, thinner ICD/CRT-D, including the unique DX platform

May 08, 2013

News Daily News

Stroke After STEMI Unusual But Carries Poor Prognosis

Yael L. Maxwell

May 03, 2013

News Daily News

La ESC Ofrece Recomendaciones para el Uso de Nuevos Anticoagulantes Orales

Yael L. Maxwell

May 03, 2013

News Daily News

ESC Offers Recommendations on Use of New Oral Anticoagulants

Yael L. Maxwell

May 03, 2013

News Industry News

ARCA biopharma and Medtronic to Collaborate on Atrial Fibrillation Clinical Trial for GencaroTM

April 22, 2013

Presentation Fellows 2013

LAA Closure for Nonvalvular Atrial Fibrillation

Presenter: Mark Reisman

April 17, 2013

News Daily News

ASAP Published: Watchman a Safe Option for A-fib Patients Ineligible for Warfarin

Yael L. Maxwell

April 12, 2013

News Daily News

Registro Danés: El Dabigatran es Seguro y Eficaz en el Mundo Real

Caitlin E. Cox

April 05, 2013

News Daily News

Danish Registry: Dabigatran Safe, Effective in Real-World Use

Caitlin E. Cox

April 05, 2013

Presentation

Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation

Presenter: A.R. Harrington

April 05, 2013

Presentation ECHO 2013

Advanced TEE: Clinical Decision Making in Cryptogenic Stroke and Atrial Fibrillation

Presenter: Marco R. Di Tullio

April 04, 2013

News Daily News

Yet Another Novel Anticoagulant Shows Promise for Preventing Stroke in A-fib

March 28, 2013

News Daily News

Low-Dose Rivaroxaban Reduces Thrombotic Events, Increases Bleeding After STEMI

Yael L. Maxwell

March 09, 2013

News Conference News ACC 2013

Will Watchman PREVAIL? Positive Study Pulled from ACC Meeting

Yael L. Maxwell

March 08, 2013

Presentation ACC 2013

Randomized Trial of LAA Closure vs Warfarin for Stroke/ Thromboembolic Prevention in Patients with Non-valvular Atrial Fibrillation (PREVAIL)

Presenter: David R. Holmes, Jr.

March 08, 2013

Advertisement

Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013

Novel Anticoagulants Cost-Effective vs. Warfarin in A-fib Patients

El Apixaban Superior a la Warfarin con independencia del Tipo y Duración de la FA

Apixaban Superior to Warfarin Regardless of A-fib Type, Duration

New Four-Year Data From Boston Scientific Demonstrated WATCHMAN® Device Was Superior To Warfarin For Mortality And Primary Efficacy In Patients With Atrial Fibrillation In Long Term Follow-Up Of The P

BIOTRONIK continues 50-year legacy of engineering excellence with smaller, thinner ICD/CRT-D, including the unique DX platform

Stroke After STEMI Unusual But Carries Poor Prognosis

La ESC Ofrece Recomendaciones para el Uso de Nuevos Anticoagulantes Orales

ESC Offers Recommendations on Use of New Oral Anticoagulants

ARCA biopharma and Medtronic to Collaborate on Atrial Fibrillation Clinical Trial for GencaroTM

LAA Closure for Nonvalvular Atrial Fibrillation

ASAP Published: Watchman a Safe Option for A-fib Patients Ineligible for Warfarin

Registro Danés: El Dabigatran es Seguro y Eficaz en el Mundo Real

Danish Registry: Dabigatran Safe, Effective in Real-World Use

Cost-Effectiveness of Apixaban, Dabigatran, Rivaroxaban, and Warfarin for Stroke Prevention in Atrial Fibrillation

Advanced TEE: Clinical Decision Making in Cryptogenic Stroke and Atrial Fibrillation

Yet Another Novel Anticoagulant Shows Promise for Preventing Stroke in A-fib

Low-Dose Rivaroxaban Reduces Thrombotic Events, Increases Bleeding After STEMI

Will Watchman PREVAIL? Positive Study Pulled from ACC Meeting

Randomized Trial of LAA Closure vs Warfarin for Stroke/ Thromboembolic Prevention in Patients with Non-valvular Atrial Fibrillation (PREVAIL)

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content